News
View today's 3SBio Inc stock price and latest 1530 news and analysis. Create real-time notifications to follow any changes in the live stock price.
3SBio is a leading biopharmaceutical company in China. It is one of the earliest biologics innovators in the country, launching EPIAO in 1998 and TPIAO in 2005. The current portfolio is older ...
Hosted on MSN1mon
Pfizer Licenses 3SBio Cancer Drug for Record $1.2 Billion - MSNPfizer will pay $1.25 billion upfront to license an experimental cancer drug out of China, in a deal that underscores multinational drugmakers’ growing enthusiasm for Chinese biotech innovation.
HONG KONG, Aug. 24, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023 interim results. Revenue in the first half of 2023 reached approximately ...
Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer’s deal announced two weeks earlier.
By Sherry Qin. Chinese biotech company 3SBio's shares surged early Tuesday after its around US$6 billion licensing deal with Pfizer to develop, manufacture and commercialize a promising cancer drug.
3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced. Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its ...
3SBio shared (PDF) data from the phase 2 trials in January. The biotech reported a 70.8% response rate in first-line, PD-L1-positive NSCLC patients. Combined with chemotherapy, SSGJ-707 achieved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results